Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Immatics and Bristol Myers Squibb have expanded their strategic collaboration to develop allogeneic TCR-T and CAR-T therapies. Immatics will receive an upfront payment of $60 million, with additional milestone payments of up to $700 million for each program, along with tiered royalties. The partnership will leverage Immatics’ ACTallo® platform and Bristol Myers Squibb’s oncology expertise, focusing on multiple programs. Additionally, an autologous TCR-T target will be added under their existing 2019 agreement, granting Immatics a further $20 million upfront.
Bristol Myers Squibb (NYSE: BMY) announced promising results from the Phase 2 PAISLEY study on deucravacitinib, an oral TYK2 inhibitor for moderate to severe systemic lupus erythematosus (SLE).
The study met its primary endpoint with statistically significant SLE Responder Index-4 (SRI(4)) responses at Week 32: 58.2% for deucravacitinib 3 mg BID, 49.5% for 6 mg BID, compared to 34.4% for placebo.
Secondary endpoints showed clinically meaningful improvements at Week 48.
The safety profile was consistent with earlier studies, supporting advancement to Phase 3 trials.
Bristol Myers Squibb announced FDA approval for Opdivo® (nivolumab) in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) for first-line treatment of unresectable advanced esophageal squamous cell carcinoma (ESCC). The approval follows results from the CheckMate -648 trial, which demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone. Opdivo-based therapies are now approved for five indications in upper gastroesophageal cancers, offering new treatment options regardless of PD-L1 status.
Bristol Myers Squibb (NYSE: BMY) announced the primary analysis results of the Phase 2 PILOT study for Breyanzi in adults with refractory or relapsed large B-cell lymphoma (LBCL). The treatment achieved an 80% overall response rate, with 54% of patients experiencing complete responses. The median duration of response was 12.1 months, and progression-free survival was at 9 months. Breyanzi demonstrated a manageable safety profile and improved patient-reported outcomes regarding quality of life. A supplemental Biologics License Application for this indication is under Priority Review by the FDA, with a target decision date of June 24, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Bernstein’s 38th Annual Strategic Decisions Conference on June 2, 2022, at 8:00 a.m. ET in New York. Giovanni Caforio, M.D., Board Chair and CEO, along with Samit Hirawat, Chief Medical Officer, will discuss the company’s strategies. The event will be accessible via a live webcast at investor.bms.com, with an archived version available later that day. Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (BMY) presented new research highlighting the efficacy of its cancer therapies at the 2022 ASCO and EHA meetings. Key findings include:
- Long-term survival rates from CheckMate -227 for non-small cell lung cancer (NSCLC), showing durable outcomes with Opdivo plus Yervoy.
- First disclosure of the PILOT study, showcasing Breyanzi's effectiveness in large B-cell lymphoma.
- Data from MEDALIST and BELIEVE studies indicating consistent anemia control with Reblozyl.
- New evidence supporting the LAG-3 mechanism in melanoma treatment via Opdualag.
Bristol Myers Squibb announced that the Phase 3 CheckMate -901 trial did not meet its primary endpoint of overall survival for Opdivo plus Yervoy in treating patients with metastatic urothelial carcinoma expressing PD-L1 ≥1%. Despite this, the trial continues under the guidance of an independent Data Monitoring Committee to explore other endpoints, and no new safety signals were observed. The company emphasizes its commitment to advancing research in urothelial carcinoma and looks forward to future data from ongoing studies.
Bristol Myers Squibb (NYSE: BMY) has announced the planned sale of its East Syracuse, New York manufacturing facility to LOTTE Corporation, marking a strategic move in its manufacturing network. This transaction, expected to close in the second half of 2022 pending regulatory approvals, will result in LOTTE establishing the site as its North American operations center for biologics contract development and manufacturing. The site, notable for its commercial-scale production capabilities, will continue to support BMY until the completion of the deal.
Bristol Myers Squibb (NYSE: BMY) announced positive results from the POETYK PSO long-term extension trial, revealing that the efficacy of deucravacitinib is maintained for up to two years in patients with moderate to severe plaque psoriasis. The trial showed response rates of 77.7% for PASI 75 and 58.7% for sPGA 0/1 after 60 weeks. Deucravacitinib, currently under regulatory review in the U.S., Europe, and Japan, is positioned to be the first selective TYK2 inhibitor approved for any disease. The safety profile remained consistent, with low incidence of serious adverse events.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, in Las Vegas, Nevada. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will address questions at 12:00 p.m. PT (3:00 p.m. ET). The session will be available via a live webcast on the company's investor relations website. An archived version will be accessible later that day. For further details, visit BMS.com.